ArticleHeart and vessels2026
The impact of diabetes on clinical outcomes in patients with pseudonormal left ventricular diastolic filling pattern and preserved ejection fraction.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Type 2 diabetes mellitus (DM) is a risk factor for the development of heart failure (HF) and associated with a poor prognosis. However, the impact of DM on clinical outcomes in patients with left ventricular diastolic dysfunction (LVDD) and HF with preserved ejection fraction (EF), which is the phenotype of diabetic cardiomyopathy, remains uncertain. This study aimed to investigate the impact of DM on cardiac functional changes and prognosis in patients with pseudonormal LV diastolic filling pattern (LVDFP) and preserved EF. A total of 413 patients with pseudonormal LVDFP and preserved EF who underwent follow-up echocardiography were enrolled between 2011 and 2020. The primary outcome was major adverse cardiac events (MACE) including all-cause death, non-fatal myocardial infarction, cardiac hospitalization, or stroke. Among the study population, 125 patients (30.3%) had DM. During the follow-up period (median 3.8 years [interquartile range: 2.1 to 5.6 years]), the follow-up EF comparing baseline EF was more significantly decreased in DM patients (67.3 ± 6.3 to 64.8 ± 7.5; p = 0.001) compared with non-DM patients (67.8 ± 5.8 to 66.8 ± 6.9; p = 0.03). Furthermore, compared with the non-DM patients, the DM patients significantly increased the risk of MACE (26.2% vs. 54.7%; adjusted hazard ratio, 1.68; 95% confidence interval, 1.11-2.54; p = 0.015). In patients with pseudonormal LVDFP and preserved EF, the DM was associated with the risk of worse clinical outcomes compared with the non-DM.
Indexed as
Identifiers
41566077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.